Sustained expression of therapeutic levels of human factor VIII in mice

Blood

Volumn 87, Issue 11, 1996, Pages 4671-4677

  Connelly, Sheila ^a   Gardner, Joann M ^a   Lyons, Russette M ^a   McClelland, Alan ^a   Kaleko, Michael ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8A;

ADENOVIRUS; ANIMAL EXPERIMENT; ARTICLE; DOSE RESPONSE; EXPRESSION VECTOR; GENE EXPRESSION REGULATION; GENE THERAPY; HEMOPHILIA A; HUMAN; LIVER TOXICITY; MOUSE; NONHUMAN; PLAQUE FORMING CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS REGULATION;

EID: 0029943193     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.11.4671.bloodjournal87114671     Document Type: Article

References (34)

1. Vehar GA, Lawn RM, Tuddenham EGD, Wood WI: Factor VIII and factor V: Biochemistry and Pathophysiology, in Albertini A, Lenfant CL, Mannucci PM, Sixma JJ (eds): Biotechnology of Plasma Proteins. Curr Stud Hematol Blood Transf. Basel, Karger, 1991, p 2155
2. Kaufman RJ: Biological regulation of factor VIII activity. Annu Rev Med 43:325, 1992
3. Zatloukal K, Cotten M, Berger M, Schmidt W, Wagner E, Birnstiel ML: In vivo production of human factor VIII in mice after intrasplenic implantation of primary fibroblasts transfected by receptor-mediated, adenovirus-augmented gene delivery. Proc Natl Acad Sci USA 91:5148, 1994
4. Dwarki VJ, Belloni P, Nijjar T, Smith J, Couto L, Rabier M, Clift S, Berns A, Cohen LK: Gene therapy for hemophilia A: Production of therapeutic levels of human factor VIII in vivo in mice. Proc Natl Acad Sci USA 92:1023, 1995
5. Kaufman RJ, Wasley LC, Dorner AJ: Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. J Biol Chem 263:6352, 1988
6. Kaufman RJ, Wasley LC, Davies MV, Wise RJ, Israel DI, Dorner AJ: Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in Chinese hamster ovary cells. Mol Cell Biol 9:1233, 1989
7. Pittman DD, Alderman EM, Tomkinson KN, Wang JH, Giles AR, Kaufman RJ: Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII. Blood 81:2925, 1993
8. Lynch CM, Israel DI, Kaufman RJ, Miller AD: Sequences in the coding region of clotting factor VIII act as dominant inhibitors of RNA accumulation and protein production. Hum Gene Ther 4:259, 1993
9. Hoeben RC, Fallaux FJ, Cramer SJ, van den Wollenberg JM, Van Ormondt H, Briet E, Van Der Eb AJ: Expression of the blood-clotting factor-VIII cDNA is repressed by a transcriptional silencer located in its coding region. Blood 85:2447, 1995
10. Koeberl DD, Halbert CL, Krumm A, Miller AD: Sequences within the coding regions of clotting factor VIII and CFTR block transcriptional elongation. Hum Gene Ther 6:469, 1995
11. Israel DI, Kaufman RJ: Retroviral-mediated transfer and amplification of a functional human factor VIII gene. Blood 75:1074, 1990
12. Hoeben RC, van der Jagt RC, Schoute F, Van Tilburg NH, Verbeet MP, Briet E, Van Ormondt H, Van Der Eb AJ: Expression of functional factor VIII in primary human skin fibroblasts after retrovirus-mediated gene transfer. J Biol Chem 265:7318, 1990
13. Hoeben RC, Einerhand MP, Briet E, Van Ormondt H, Valerio D, Van Der Eb AJ: Toward gene therapy in haemophilia A: Retrovirus-mediated transfer of a factor VIII gene into murine haematopoietic progenitor cells. Thromb Haemost 67:341, 1992
14. Hoeben RC, Fallaux FJ, Van Tilburg NH, Cramer SJ, Van Ormondt H, Briet E, Van Der Eb AJ: Toward gene therapy for hemophilia A: Long-term persistence of factor VIII-secreting fibroblasts after transplantation into immunodeficient mice. Hum Gene Ther 4:179, 1993
15. Connelly S, Smith TAG, Dhir G, Gardner JM, Mehaffey MG, Zaret KS, McClelland A, Kaleko M: In vivo gene delivery and expression of physiological levels of functional human factor VIII in mice. Hum Gene Ther 6:185, 1995
16. Connelly S, Gardner JM, McClelland A, Kaleko M: High level tissue-specific expression of functional human FVIII in mice. Hum Gene Ther 7:183, 1996
17. Kozarsky KF, Wilson JM: Gene therapy: Adenovirus vectors. Curr Opin Genet Dev 3:499, 1993
18. Smith TAG, Mehaffey MG, Kayda DB, Saunders JM, Yei S, Trapnell BC, McClelland A, Kaleko M: Adenovirus-mediated expression of therapeutic plasma levels of human factor IX in mice. Nat Genet 5:397, 1993
19. Tolstoshev P, Mittereder N, Yei S, Trapnell BC: Adenovirus vectors for gene therapy, in Cancer Chemotherapy: Challenges for the Future. Tokyo, Japan, Excerpta Medica, Ltd, 1994, p 23
20. Rosenfeld MA, Yoshimura K, Trapnell BC, Yoneyama K, Rosenthal ER, Dalemans W, Fukayama M, Bargon J, Stier LE, Stratford Perricaudet L, Perricaudet M, Guffino, WB Pavirani, A Lecodq J-P, Crystal RG: In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 68:143, 1992
21. Toole JJ, Knopf JL, Wozney JM, Sultzman PA, Buecker J, Pittman DD, Kaufman RJ, Brown E, Shoemaker C, Orr EC, Amphlett GW, Foster WB, Coe ML, Knutson GJ, Fass DN, Hewick RM: Molecular cloning of a cDNA encoding antihemophiliac factor. Nature 312:342, 1984
22. Wood WI, Capon DJ, Simonsen CC, Eaton DL, Gitschier J, Keyt B, Seeburg PH, Smith DH, Hollingshead P, Wion KL, Delwart E, Tuddenham EGD, Vehar GA, Lawn RM: Expression of active human factor VIII from recombinant DNA cloned. Nature 312:330, 1984
23. Quimby FW: The mouse, in Loeb WF, Quimby FW (eds): The Clinical Chemistry of Laboratory Animals. Oxford, UK, Pergamon, 1989, p 3
24. Li Q, Kay MA, Finegold M, Stratford-Perricaudet LD, Woo SLC: Assessment of recombinant adenoviral vectors for hepatic gene therapy. Hum Gene Ther 4:403, 1993
25. Yang Y, Nunes FA, Berencsi K, Furth EE, Gönczöl E, Wilson JM: Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 91:4407, 1994
26. Yang Y, Ertl HCJ, Wilson JM: MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunology 1:433, 1994
27. Yang Y, Wilson JM: Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo. J Immunol 155:2564, 1995
28. Engelhardt JF, Ye X. Doranz B, Wilson JM: Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA 91:6196, 1994
29. Fang B, Eisensmith RC, Wang R, Cross RE, Landen CN, Gordon G, Bellinger DA, Read MS, Hu PC, Brinkhous KM, Woo SLC: Gene therapy for hemophilia B: Host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression. Hum Gene Ther 6:1039, 1995
30. Dai Y, Schwarz EM, Gu D, Zhang W, Sarvetnick N, Verma IM: Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA 92:1401, 1995
31. Barr D, Tubb J, Ferguson D, Scaria A, Lieber A, Wilson C, Perkins J, Kay MA: Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: Comparisons between immunocompetent and immunodeficient inbred strains. Gene Ther 2:151, 1995
32. Kay MA, Landen CN, Rothenberg SR, Taylor LA, Leland F, Wiehle S, Fang B, Bellinger D, Finegold M, Thompson AR, Read M, Brinkhous KM, Woo SL: In vivo hepatic gene therapy: Complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proc Natl Acad Sci USA 91:2353, 1994
33. Scheibel E, Ingerslev J, Dalsgaard-Nielsen J, Stenbjerg S, Knudsen JB: Continuous high-dose factor VIII for the induction of immune tolerance in haemophilia A patients with high responder state: A description of eleven patients treated. Thromb Haemost 58:1049, 1987
34. Mariani G, Ghirardini A, Bellocco R: Immune tolerance in hemophilia-principal results from the International Registry. Report of the factor VIII and IX Subcommittee. Thromb Haemost 72:155, 1994